TestaVec is accelerating the fight against cancer and a range of rare genetic diseases using the world’s first human cell based in vitro platform with which to test the safety of viral vectors used to deliver gene therapy. The TestaVec in-vitro platform provides for primary culture, viral infection and differentiation of human iPSc cells and molecular analysis of clinically-relevant molecular biomarkers of vector - induced genotoxicity. Avoiding animal models that give biased oncogenic outreads, this leap in innovation from animal to human cell-based vector testing aims to accelerate the timeline to commercialisation for gene therapy products to reach the market to treat patients in need with once in a life-time medical care. Together with Precision Biology leaders, GeneWerk, we have created a battery of tests to bridge the gap between pre-clinical and clinical vector safety testing. Our platform allows for specific test parameters to be customised to address the specific needs of both developers and manufacturers, satisfying an as yet unmet need in vector safety testing.